You are here

Blenrep

JPM23: Is GSK's 15-day accelerated approval withdrawal the new normal? Hear FDA Commissioner Robert Califf's response

JPM23: Is GSK's 15-day accelerated approval withdrawal the new normal? Hear FDA Commissioner Robert Califf's response

Fierce Pharma

Flag link:

GSK’s “crown jewels” already look tarnished

GSK’s “crown jewels” already look tarnished

EP Vantage

Flag link:

GSK to pull blood cancer drug from US market after study failure

GSK to pull blood cancer drug from US market after study failure

BioPharma Dive

clinical trials

Multiple Myeloma

Flag link:

Time for GSK to stop dreaming about Blenrep

Time for GSK to stop dreaming about Blenrep

EP Vantage

clinical trials

Multiple Myeloma

Flag link:

GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep

GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep

Fierce Biotech

antibody-drug conjugate

Flag link: